Design Therapeutics, Inc. Common Stock
Symbol: DSGN (NASDAQ)
5.71
▲ (3.25%) 0.180
Company Description:
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
Key Stats
- Today's Open: $5.51
- Today's High: $5.75
- Today's Low: $5.4
- Today's Volume: 96.83K
- Yesterday Close: $5.53
- Yesterday High: $5.625
- Yesterday Low: $5.28
- Yesterday Volume: 106.62K
- Last Min Volume: 1
- Last Min High: $5.71
- Last Min Low: $5.71
- Last Min VWAP: $5.71
Company Profile
- Name: Design Therapeutics, Inc. Common Stock
- Website: https://www.designtx.com
- Listed Date: 2021-03-26
- Location: CARLSBAD, CA
- Market Status: Active
- CIK Number: 0001807120
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $320.62M
- Round Lot: 100
- Outstanding Shares: 56.95M
- Asset Type: CS
RECENT FILINGS FOR DSGN
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-10 | 4 | View |
| 2025-09-10 | 3 | View |
| 2025-09-10 | 8-K | View |
| 2025-08-28 | SCHEDULE 13G | View |
| 2025-08-14 | 4 | View |
| 2025-08-13 | 144 | View |
| 2025-08-13 | 144 | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 4 | View |
| 2025-06-12 | 8-K | View |
| 2025-05-23 | 4 | View |
| 2025-05-23 | 3 | View |
| 2025-05-16 | EFFECT | View |
| 2025-05-14 | CORRESP | View |
Latest News on DSGN